Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of
Critical Care and Emergency Medicine ISSN: 2474-3674

Citation

Abdelmonem S, Helmy T, El Sayed I, Ghazal S (2019) A Prospective Study on Severe Hypotension in Critically Ill Patients Sedated with Propofol. Int J Crit Care Emerg Med 5:078. doi.org/10.23937/2474-3674/1510078

Copyright

© 2019 Abdelmonem S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ORIGINAL RESEARCH | OPEN ACCESSDOI: 10.23937/2474-3674/1510078

A Prospective Study on Severe Hypotension in Critically Ill Patients Sedated with Propofol

Sherif Abdelmonem1, Tamer Helmy1, Iman El Sayed2* and Salma Ghazal1

1Department of Critical Care Medicine, Faculty of Medicine, Alexandria University, Egypt

2Department of Biomedical Informatics and Medical Statistics, Medical Research Institute, Alexandria University, Egypt

Abstract

Background

We aimed to verify if mean arterial pressure (MAP) at initiation of Propofol infusion and the APACHE score can predict the risk of severe hypotension.

Methods

A prospective study on 100 patients treated with Propofol during their stay at the Main University Hospital between 2017 and 2018. We estimated relative risks (RRs) of severe hypotension according to MAP and APACHE score categories using a modified Poisson model for binary outcome.

Results

Fifty-three patients developed severe hypotension. Compared to patients with MAP ≥ 100 mmHg, the RR were: 3.59 (95% CI: 1.68; 7.67) for patients with MAP between 80 and 100 mmHg and 5.28 (95% CI: 2.48; 11.21) for patients with MAP < 80. Patients with APACHE II score between 10-15 had a RR of 4.00 (95% CI: 2.11; 7.59) compared to patients with APACHE score below 10 points. The RR was 4.83 (95% CI: 2.65; 8.80) for those with APACHE II score > 15 points.

Conclusion

Clinicians should use Propofol with caution in patients having low baseline MAP and high APACHE score.